A multicenter, open-label, single-arm phase II study (@Be trial) that evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy in 39 non-squamous NSCLC patients with a PD-L1 tumor proportion score of ≥50% was conducted by the West Japan Oncology Group, and the results were reported at the 2020 European Society for Medical Oncology conference (103). Here, CD274 is linked to neoplasm.